- Home
- KNOP vs PROK Comparison
KNOP vs PROK Comparison
Compare KNOP & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNOP | PROK |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 366.5M | 331.2M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | KNOP | PROK |
|---|---|---|
| Price | $10.48 | $2.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 109.6K | ★ 1.1M |
| Earning Date | 12-04-2025 | 11-10-2025 |
| Dividend Yield | ★ 1.00% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.17 | N/A |
| Revenue | ★ $352,712,000.00 | $744,000.00 |
| Revenue This Year | $14.84 | $956.51 |
| Revenue Next Year | $1.98 | N/A |
| P/E Ratio | $8.90 | ★ N/A |
| Revenue Growth | ★ 17.65 | N/A |
| 52 Week Low | $5.29 | $0.46 |
| 52 Week High | $11.10 | $7.13 |
Technical Indicators
Market Signals| Indicator | KNOP | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 42.89 |
| Support Level | $10.06 | $2.15 |
| Resistance Level | $11.10 | $2.32 |
| Average True Range (ATR) | 0.27 | 0.14 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 40.38 | 10.34 |
Price Performance
Historical ComparisonAbout KNOP KNOT Offshore Partners LP
KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.